InMed Pharmaceuticals (INM) Current Assets (2020 - 2026)
InMed Pharmaceuticals (INM) posted quarterly Current Assets of $6.9 million for Q1 2026, up 7.46% year-over-year from $6.4 million in Q1 2025, and down 21.63% quarter-over-quarter from $8.8 million in Q4 2025.
InMed Pharmaceuticals (INM) Current Assets (2020 - 2026) Analysis & Trends
InMed Pharmaceuticals' Current Assets history runs 7 years deep, the most recent figure standing at $6.9 million for Q1 2026.
- In Q1 2026, Current Assets rose 7.46% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $6.9 million (up 7.46% YoY), while the FY2025 annual figure was $12.9 million, up 48.08% from the prior year.
- Current Assets for Q1 2026 stood at $6.9 million, down from $8.8 million in the prior quarter.
- The five-year high for Current Assets was $14.0 million in Q4 2022, with the low at $5.5 million in Q4 2024.
- The 5-year median for Current Assets is $9.6 million (2022), against an average of $9.7 million.
- The sharpest annual moves came in 2024 and 2025: Current Assets sank 53.68% in 2024, then jumped 60.67% in 2025.
- InMed Pharmaceuticals' Current Assets stood at $14.0 million in 2022, then slipped by 15.75% to $11.8 million in 2023, then tumbled by 53.68% to $5.5 million in 2024, then surged by 60.67% to $8.8 million in 2025, then decreased by 21.63% to $6.9 million in 2026.
- Business Quant data shows INM's Current Assets at $6.9 million in Q1 2026, $8.8 million in Q4 2025, and $10.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 5.76 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 13.76 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 6.36 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 19.76 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 3.48 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 10.06 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 1.64 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.80 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 3.22 Bn |
| 10 | InMed Pharmaceuticals | 6.38 Mn | 1.14 Mn | - | 6.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.89 Mn |
| Dec 31, 2025 | 8.79 Mn |
| Sep 30, 2025 | 10.80 Mn |
| Jun 30, 2025 | 12.87 Mn |
| Mar 31, 2025 | 6.41 Mn |
| Dec 31, 2024 | 5.47 Mn |
| Sep 30, 2024 | 7.28 Mn |
| Jun 30, 2024 | 8.69 Mn |
| Mar 31, 2024 | 10.06 Mn |
| Dec 31, 2023 | 11.81 Mn |
| Sep 30, 2023 | 8.30 Mn |
| Jun 30, 2023 | 11.33 Mn |
| Mar 31, 2023 | 11.84 Mn |
| Dec 31, 2022 | 14.02 Mn |
| Sep 30, 2022 | 11.54 Mn |
| Jun 30, 2022 | 9.60 Mn |
| Mar 31, 2022 | 8.75 Mn |
| Dec 31, 2021 | 12.51 Mn |
| Sep 30, 2021 | 15.98 Mn |
| Jun 30, 2021 | 8.38 Mn |